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INTRODUCTION
Benign prostatic hyperplasia (BPH) is one of the most 
common disease processes affecting the aging male1, 
while prostate cancer is the most common non-skin 
cancer among men worldwide2 and the second lead-
ing cause of deaths from cancer in men in the United 
States and Europe3. Despite the prevalence and clini-
cal implications of BPH and prostate cancer, surpris-
ing little is known about the pathophysiology of the 
diseases. Besides the efforts for pharmacotherapy and 
surgical treatment, there is considerable effort devoted 
in detecting BPH and/or prostate cancer in the early 
stages, with curative intent, to decrease overall and 
disease specific morbidity and mortality4.
Besides hormones, cytokines and growth factors 
there is increasing evidence that molecules of the ex-
tracellular matrix (ECM) may be an alternative tar-
get to this end5. The ECM of the prostate contributes 
significantly in the structural framework of the organ6 
and there is evidence that the ECM is involved in in-
tercellular trafficking of steroid hormones and growth 
factors7 and in the regulation of epithelial cell prolif-
eration8, indicating that BPH may be the consequence 
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of alterations in ECM components affecting stromal 
- epithelial interactions. 
ECM molecules, particularly glycoproteins, gly-
cosaminoglycans (GAG) and proteoglycans, comprise 
a fibrous network that separates prostate stromal from 
epithelial elements. GAG molecules that is chondroi-
tin and dermatan sulphates (CS, DS), hyaluronic acid 
(HA), heparin and heparan sulphate (HS), and keratan 
sulphate (KS)9,10 regulate cell proliferation, cell-to-
cell interactions, as well as the action of growth fac-
tors. In pathologic situations, such as benign prostatic 
hyperplasia (BPH) and prostate cancer, GAG influ-
ence the diffusion rates of messenger molecules with-
in and between tissues11, affecting cell proliferation 
and/or migration12-14. GAG homeostasis in the pros-
tate may be regulated by hormones because castration 
and androgen/oestrogen treatment significantly affect 
stromal deposition of prostate GAG15. With respect to 
individual GAG, DS has been reported to decrease16 
and CS to increase cell proliferation15,16. Increases in 
CS levels may be associated with hyperplasic changes 
of the prostate gland17-19, although we have previously 
shown that in patients with BPH the prostate content 
of CS is significantly enhanced, whereas DS is signifi-
cantly reduced20.
Among GAG, hyaluronic acid, which consists of 
repeating units of D-glucuronic acid and N-acetyl-
glucosamine21, is of particular interest, since it has 
been shown that its synthesis is increased by cancer 
cells22 and to facilitate the proliferation and metasta-
sis of cancer cells via its CD44 and RHAMM recep-
tors23-26. Implantation of tumor cell lines that differ in 
their capacity to synthesize hyaluronic acid in mice 
indicated that the cell line with higher rate of hyal-
uronic acid synthesis gave significantly higher num-
ber of metastasis27.
HA has been in focus for several clinical applica-
tions because it is an immunoneutral polysaccharide, 
found in abundance in the human body, and is es-
sential in the pathophysiology of many cellular and 
tissue functions9-13. Chemically modified HA can be 
transformed into many physical forms, such as soft 
or stiff hydrogels, viscoelastic solutions, non-woven 
meshes, electrospun fibers, macroporous and fibrillar 
sponges, nanoparticulate fluids and flexible sheets for 
use in a range of preclinical and clinical settings28. In 
addition HA can be produced in streches of varying 
molecular mass, apparently with different physiologi-
cal functions9. Thus, endogenous levels of HA may 
be modified accordingly by administration or by in-
tervening on the expression of enzymes involved in 
the homeostasis of HA9. HA synthases (termed HAS 
1, HAS 2 and HAS 3) have distinct catalytic rates, 
resulting to HA products of different molecular mass: 
HAS 1 and HAS 2 synthesize relatively long stretches 
(2-4 x 106 Da), associated with stress-induced con-
ditions and wound healing, while HAS 3 polymer-
izes short stretches of disaccharide chains (0.4-2.5 x 
105 Da) that may be involved in activation of signal 
transduction9. HA is metabolized by hyaluronidases 
(HYAL), mainly by HYAL 1 and HYAL 2, present in 
various tissues9.
The aim of this study was to further clarify the in-
volvement of hyaluronic acid in prostate pathology. 
We compared the immunohistochemical expression 
of hyaluronic acid in the normal prostate, BPH and 
prostate carcinoma. We found that the amount of hy-
aluronic acid in the stroma was markedly increased 
in prostate carcinoma samples indicating that hyal-
uronic acid may be a supplementary tumor-associated 
marker.
MATERIALS AND METHODS
Tissue sections: Twenty two prostate tissue samples 
were selected from the archives of the Department 
of Pathology, G. Gennimatas Hospital. The samples 
were fixed in formalin, embedded in paraffin, cut at 
5μm and stained with haematoxylin and eosin for his-
tological typing and grading. Six histologically nor-
mal prostate tissue samples from cystoprostatectomy 
specimens were included, as well as 10 benign prostat-
ic hyperplasia samples. The results were compared to 
a group of 6 prostate cancer samples obtained during 
radical prostatectomy. The patients had not received 
hormonal therapy prior to radical prostatectomy.
Immunohistochemical staining
The sections were deparaffinized in xylene, rehydrat-
ed with graded alcohols and washed with PBS. En-
dogenous peroxidase was blocked with 0.5% H2O2 for 
20 min and non-specific binding was blocked with 1% 
BSA in PBS for 30 min. The sections were incubated 
with biotinylated haluronic acid binding protein (B-
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HABP, Seikagaku Corporation, Tokyo, Japan). The 
concentration of the protein was 2.5 μg/ml, diluted 
in PBS, and the incubation was carried out overnight 
at 4oC. The slides were then washed with PBS and 
treated with avidin-biotin-peroxidase (StreptABCom-
plex/HRP, Dako, Glostrup, Denmark) for 1h at room 
temperature according to the manufacturer’s instruc-
tions. After further washing, the slides were treated 
with Sigma Fast (Sigma, St. Louis, USA) for color 
development according to the manufacturer’s instruc-
tions. Finally, the preparations were washed in water, 
counterstained with Mayer’s haematoxylin and finally 
dehydrated and mounted.
Negative controls included sections incubated 
without B-HABP as well as sections incubated with 
50 U/ml Streptomyces hylauronidase (Seikagaku Cor-
poration, Tokyo, Japan) for 3h at 37oC.
Image analysis: Densitometric scanning of hyal-
uronic acid staining was performed using a computer-
assisted image analysis program (1D Image Analysis 
Software, Kodak Digital Science v.3.0, Eastman Ko-
dak, Rochester, NY, USA). Results were quantified 
and a staining score was calculated based on the area 
of staining and staining intensity.
RESULTS
Six different normal prostates and ten benign pros-
tatic hyperplasia specimens were used to determine 
the localization and distribution of hyaluronan in 
nonmalignant prostate tissue. Staining was localized 
predominantly in the stroma surrounding normal and 
hyperplastic prostate glands (Figure 1A), as well as in 
the fibrovascular core of the papillary projections in 
those glands (Figure 1B). The smooth muscular ele-
ment of the prostatic stroma did not stain, in contrast 
to the fibrous element. Few (<1%) epithelial cells, 
basal as well as cuboidal, showed cytoplasmic stain-
ing. Control slides treated first with hyaluronidase did 
not stain, showing the specificity of the probe (data 
not shown).
In contrast to normal and hyperplastic prostate 
tissue, there was a marked increase in the amount of 
hyaluronan in cancerous prostate in the six samples 
studied. Hyaluronan was distributed throughout the 
tumor stroma with a rather sharp diminution at the 
interface between tumor stroma and nontumoral con-
nective tissue (Figure 1C). In contrast to nonmalig-
Figure 1. (A) Localization and distribution of hyaluronic acid 
in nonmalignant prostate tissue. Staining was localized pre-
dominantly in the stroma surrounding normal prostate glands. 
(250x). (B) Localization and distribution of hyaluronic acid 
in hyperplastic prostate glands. Staining was localized in the 
stroma surrounding BPH prostate glands, but predominantly 
in the fibrovascular core of the papillary projections (black 
arrow) of those glands. (250x). (C) Localization and distribu-
tion of hyaluronic acid in cancerous prostate. In this Glea-
son 3 prostate cancer specimen, hyaluronic acid is distributed 
throughout the tumor stroma with a rather sharp diminution 
at the interface between tumor stroma and nontumoral con-
nective tissue. In contrast to nonmalignant tissue, staining 
in tumor samples was diffuse throughout the stroma and not 
predominantly localized around glandular structures. (250x).
4 Aristotle University Medical Journal, Vol. 39, Issue 2, June 2012
nant tissue, stromal staining was diffuse throughout 
the stroma and not predominantly localized around 
glandular structures. The presence of few (<1%) scat-
tered malignant cells that showed cytoplasmic stain-
ing was noted. 
Image analysis indicated that in prostate cancer 
specimen, hyaluronic acid was immunohistochemi-
cally overexpressed by as much as five-fold as com-
pared to BPH or normal prostate (Figure 2), while the 
difference between BPH and benign prostate was non 
significant.
DISCUSSION
There were no statistical differences observed in the 
content of hyaluronic acid between normal prostate 
and BPH. In BPH, staining was localized in the stro-
ma surrounding the glands, but predominantly in the 
fibrovascular core of the papillary projections of those 
glands. In contrast, there was considerable increase 
(5x) in hyaluronic acid staining in samples from pros-
tates with cancer. In the latter case, staining was dif-
fuse throughout the stroma and not predominantly lo-
calized around glandular structures.
This observation may be associated with the bi-
ology of cancer in the prostate gland and is in good 
correlation with previous reports regarding hyaluronic 
acid and prostate or other tissues. In this respect it has 
been reported that high levels of hyaluronic acid in 
the stroma of prostate cancer are associated with low 
differentiation, high mitotic activity and metastasis29. 
Furthermore, hyaluronic acid has been shown to inter-
fere with the distribution and absorption of antitumor 
agents30 and hyaluronidase enhanced the penetration 
of the chemotherapeutic doxorubicin in lung and la-
ryngeal squamous carcinoma cell lines31. It has also 
been reported that hyaluronic acid may inhibit im-
mune responses32, while small fragments of hyaluron-
ic acid (3 to 16 disaccharides) promote angiogenesis33 
and a hexasaccharide enhances endothelia cell migra-
tion and lumen formation of new vessels34.
Although hyaluronic acid has not been shown to 
offer any advantages over other markers for prostate 
cancer, it appears that this GAG may be proved to be 
a supplementary tumor-associated marker. Insight 
gained in the mechanisms of controlling the homeo-
stasis of hyaluronic acid via increased production 
and hyaluronidases or hyaluronic acid synthases may 
eventually lead to new targets for pharmacological in-
tervention in the treatment of human prostate cancer.
Figure 2. Immunohistochemical hyaluronic acid expression in normal, BPH and cancerous prostate glands. Staining score 
(vertical axis) was calculated based on the immunohistochemically positive staining area as well as staining intensity. Mean 
values ± SEM for n samples are shown.
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